Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02921828 · ClinicalTrials.gov registry record
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
A clinical trial, sponsored by Celgene.
- Completed
- Registry status
- 1,149
- Enrollment target
NCT02921828 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 1,149 participants.
The verdict
NCT02921828 has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 1,149 participants
- Enrollment target
Study Summary
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form of the surveillance will be completed at the time when the planned number of patients to be enrolled is reached. During a period until conditions for approval are removed, a system enabling to retrospectively collect appropriate information based on patient data from RevMate® will be, as necessary, maintained. 2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the start date of release of Pomalyst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,149 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2015-12-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02921828
The ClinicalTrials.gov registry entry for NCT02921828 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02921828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02921828 about?
NCT02921828 is a clinical study titled "A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg". 1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form of the surveillance will be completed at the time when the planned numb...
What is the current status of trial NCT02921828?
This trial is currently completed. The enrollment target is 1,149 participants. The study started on 2015-04-30. Estimated completion is 2015-12-10.
Who is sponsoring clinical trial NCT02921828?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.